百濟神州(06160.HK)將於美國臨床腫瘤學會年會上披露核心產品臨床數據
百濟神州(06160.HK)公布,將於芝加哥舉行的2023年美國臨床腫瘤學會(ASCO)年會上公布其研發管線的最新數據,即將公布的進展包括百濟神州核心產品澤布替尼(中文商品名:百悅澤)與替雷利珠單抗(中文商品名:百澤安)的臨床數據,以及其OX40激動劑和BCL-2抑制劑的早期研究結果。
公司指出,核心藥物繼續表現出一致的安全性和有效性特徵。此外,百濟神州的試驗用新藥BGB-A445是一種新型單克隆抗體OX40激動劑,不會競爭性阻斷OX40與其天然配體結合。該新藥的首次人體試驗結果即將於ASCO年會上展示。BGB-A445單藥或與替雷利珠單抗聯合用於治療晚期實體瘤患者,在所有劑量下的總體耐受性均良好,無劑量限制性毒性,並表現出初步抗腫瘤活性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.